103 related articles for article (PubMed ID: 29555478)
1. Inhibition of TACC3 by a small molecule inhibitor in breast cancer.
Campo L; Breuer EK
Biochem Biophys Res Commun; 2018 Apr; 498(4):1085-1092. PubMed ID: 29555478
[TBL] [Abstract][Full Text] [Related]
2. TACC3 promotes epithelial-mesenchymal transition (EMT) through the activation of PI3K/Akt and ERK signaling pathways.
Ha GH; Park JS; Breuer EK
Cancer Lett; 2013 May; 332(1):63-73. PubMed ID: 23348690
[TBL] [Abstract][Full Text] [Related]
3. A Highly Potent TACC3 Inhibitor as a Novel Anticancer Drug Candidate.
Akbulut O; Lengerli D; Saatci O; Duman E; Seker UOS; Isik A; Akyol A; Caliskan B; Banoglu E; Sahin O
Mol Cancer Ther; 2020 Jun; 19(6):1243-1254. PubMed ID: 32217742
[TBL] [Abstract][Full Text] [Related]
4. Transforming acidic coiled-coil-containing protein 3 (TACC3) overexpression in hepatocellular carcinomas is associated with "stemness" and epithelial-mesenchymal transition-related marker expression and a poor prognosis.
Nahm JH; Kim H; Lee H; Cho JY; Choi YR; Yoon YS; Han HS; Park YN
Tumour Biol; 2016 Jan; 37(1):393-403. PubMed ID: 26219896
[TBL] [Abstract][Full Text] [Related]
5. TACC3 promotes stemness and is a potential therapeutic target in hepatocellular carcinoma.
Zhou DS; Wang HB; Zhou ZG; Zhang YJ; Zhong Q; Xu L; Huang YH; Yeung SC; Chen MS; Zeng MS
Oncotarget; 2015 Sep; 6(27):24163-77. PubMed ID: 26219398
[TBL] [Abstract][Full Text] [Related]
6. Discovery of novel analogs of KHS101 as transforming acidic coiled coil containing protein 3 (TACC3) inhibitors for the treatment of glioblastoma.
Zhao W; Sun X; Shi L; Cai SZ; Ma ZR
Eur J Med Chem; 2022 Dec; 244():114874. PubMed ID: 36332551
[TBL] [Abstract][Full Text] [Related]
7. Targeting TACC3 represents a novel vulnerability in highly aggressive breast cancers with centrosome amplification.
Saatci O; Akbulut O; Cetin M; Sikirzhytski V; Uner M; Lengerli D; O'Quinn EC; Romeo MJ; Caliskan B; Banoglu E; Aksoy S; Uner A; Sahin O
Cell Death Differ; 2023 May; 30(5):1305-1319. PubMed ID: 36864125
[TBL] [Abstract][Full Text] [Related]
8. TACC3 is essential for EGF-mediated EMT in cervical cancer.
Ha GH; Kim JL; Breuer EK
PLoS One; 2013; 8(8):e70353. PubMed ID: 23936413
[TBL] [Abstract][Full Text] [Related]
9. Localization of human TACC3 to mitotic spindles is mediated by phosphorylation on Ser558 by Aurora A: a novel pharmacodynamic method for measuring Aurora A activity.
LeRoy PJ; Hunter JJ; Hoar KM; Burke KE; Shinde V; Ruan J; Bowman D; Galvin K; Ecsedy JA
Cancer Res; 2007 Jun; 67(11):5362-70. PubMed ID: 17545617
[TBL] [Abstract][Full Text] [Related]
10. TACC3 deregulates the DNA damage response and confers sensitivity to radiation and PARP inhibition.
Ha GH; Kim JL; Petersson A; Oh S; Denning MF; Patel T; Breuer EK
Oncogene; 2015 Mar; 34(13):1667-78. PubMed ID: 24769898
[TBL] [Abstract][Full Text] [Related]
11. Polo-like kinase 1 induces epithelial-to-mesenchymal transition and promotes epithelial cell motility by activating CRAF/ERK signaling.
Wu J; Ivanov AI; Fisher PB; Fu Z
Elife; 2016 Mar; 5():. PubMed ID: 27003818
[TBL] [Abstract][Full Text] [Related]
12. PARP3 controls TGFβ and ROS driven epithelial-to-mesenchymal transition and stemness by stimulating a TG2-Snail-E-cadherin axis.
Karicheva O; Rodriguez-Vargas JM; Wadier N; Martin-Hernandez K; Vauchelles R; Magroun N; Tissier A; Schreiber V; Dantzer F
Oncotarget; 2016 Sep; 7(39):64109-64123. PubMed ID: 27579892
[TBL] [Abstract][Full Text] [Related]
13. Transforming acidic coiled-coil 3 and Aurora-A interact in human thyrocytes and their expression is deregulated in thyroid cancer tissues.
Ulisse S; Baldini E; Toller M; Delcros JG; Guého A; Curcio F; De Antoni E; Giacomelli L; Ambesi-Impiombato FS; Bocchini S; D'Armiento M; Arlot-Bonnemains Y
Endocr Relat Cancer; 2007 Sep; 14(3):827-37. PubMed ID: 17914111
[TBL] [Abstract][Full Text] [Related]
14. Targeted inhibition of Polo-like kinase 1 by a novel small-molecule inhibitor induces mitotic catastrophe and apoptosis in human bladder cancer cells.
Zhang Z; Zhang G; Kong C
J Cell Mol Med; 2017 Apr; 21(4):758-767. PubMed ID: 27878946
[TBL] [Abstract][Full Text] [Related]
15. Suppression of centrosome protein TACC3 induces G1 arrest and cell death through activation of p38-p53-p21 stress signaling pathway.
Suhail TV; Singh P; Manna TK
Eur J Cell Biol; 2015 Feb; 94(2):90-100. PubMed ID: 25613365
[TBL] [Abstract][Full Text] [Related]
16. The pan-inhibitor of Aurora kinases danusertib induces apoptosis and autophagy and suppresses epithelial-to-mesenchymal transition in human breast cancer cells.
Li JP; Yang YX; Liu QL; Zhou ZW; Pan ST; He ZX; Zhang X; Yang T; Pan SY; Duan W; He SM; Chen XW; Qiu JX; Zhou SF
Drug Des Devel Ther; 2015; 9():1027-62. PubMed ID: 25733818
[TBL] [Abstract][Full Text] [Related]
17. Negative regulation of BRCA1 by transforming acidic coiled-coil protein 3 (TACC3).
Kim JL; Ha GH; Campo L; Breuer EK
Biochem Biophys Res Commun; 2018 Feb; 496(2):633-640. PubMed ID: 29355525
[TBL] [Abstract][Full Text] [Related]
18. Resveratrol inhibits cell cycle progression by targeting Aurora kinase A and Polo-like kinase 1 in breast cancer cells.
Medina-Aguilar R; Marchat LA; Arechaga Ocampo E; Gariglio P; García Mena J; Villegas Sepúlveda N; Martínez Castillo M; López-Camarillo C
Oncol Rep; 2016 Jun; 35(6):3696-704. PubMed ID: 27109433
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological evaluation of polo-like kinase 1/eukaryotic elongation factor 2 kinase (PLK1/EEF2K) dual inhibitors for regulating breast cancer cells apoptosis and autophagy.
Pan Z; Chen Y; Liu J; Jiang Q; Yang S; Guo L; He G
Eur J Med Chem; 2018 Jan; 144():517-528. PubMed ID: 29288948
[TBL] [Abstract][Full Text] [Related]
20. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy.
Tan J; Li Z; Lee PL; Guan P; Aau MY; Lee ST; Feng M; Lim CZ; Lee EY; Wee ZN; Lim YC; Karuturi RK; Yu Q
Cancer Discov; 2013 Oct; 3(10):1156-71. PubMed ID: 23887393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
